This is a past event. Registration is closed. View other FORTUNE China events.
Jui Tan
Managing Partner of BlueRun Ventures ChinaJui Tan is the Managing Partner of BlueRun Ventures China. He joined BlueRun Ventures US in 2000 and started BlueRun China in 2005. With over 20 years of venture capital experience, Jui has been recognized among the top 100 venture capitalists worldwide by Forbes Midas List and as the No.1 early-stage investor in China by Zero2IPO. He has been also named as a top venture capitalist and early-stage investor in China by ChinaVenture, Forbes China, and 36Kr.
He has led the investment in excellent early projects such as Ganji.com, PPTV, QingCloud (600316.SH), Yiautos, and i-Kingtec. He also participated in many major strategic mergers and acquisitions in the industry such as Ganji.com/58.com.
Jui is an active early-stage investor in enterprise service and high-tech. Prior to joining the firm, Jui held various management positions within Singapore Telecom, most recently served as a Director of Global Service Development, responsible for SingTel's managed data and voice services globally. Prior to this, he held engineering management positions at IBM, focusing on computing and networking systems.
Jui received his B.S. in Electrical & Electronics Engineering from Nanyang Technological University, Singapore, and M.B.A. from the International Institute of Management Development (IMD) in Switzerland.
Feng Deng
Founding Managing Partner, Northern Light Venture Capital (NLVC)Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He has more than 15 years of technical and managerial experience spanning the computing, communication, and data networking industries, in addition to his nearly two decades of investment leadership. Currently, Feng oversees upwards of $4.5 billion across 5 USD funds and 5 RMB funds.
Throughout his career, he has focused on early-stage investments across the science and technology sectors, and he continues his commitment to cultivating world-class Chinese enterprises and supporting entrepreneurs in these sectors to this day. The portfolio companies that Feng has invested in and managed include Meituan, ThunderSoft, GigaDevice, Hillstone Networks, Aerohive Networks, Spreadtrum, Tencent Music, LineKong, ChineseAll, LianLian, Baihe, BGI, Zelgen, CITIC Pharma, Burning Rock Biotech, Taimei Technology, and more.
Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on the NASDAQ in 2001 and was acquired less than three years later by Juniper Networks in 2004 for $4.2 billion.
In addition to his role at NLVC, Feng serves on the Board of Directors of Tsinghua University Foundation and is Director of Schwarzman College at Tsinghua University, a Distinguished Visiting Professor of Tsinghua University, the Chairman of the Asia Advisory Board of the USC Viterbi School of Engineering, an Advisory Board member of the Stanford Institute for Economic Policy Research (SIEPR), a member of the Asia Council of Wharton School, a member of the China Council of Harvard GSAS, the Deputy Director General of China Entrepreneur Club, and the rotating president of Future Forum.
Feng holds BS and MS degrees in electrical engineering from Tsinghua University, an MS degree in computer engineering from the University of Southern California, and an MBA from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.
Leo Duan
Partner at HedosophiaLeo Duan is a Partner at Hedosophia, a London based global technology fund, and the head of China. Leo founded the Hedosophia China operation in 2020. Prior to joining Hedosophia, Leo is an investor at Sequoia Capital China. Leo holds a Bachelor’s degree from Amherst College.
Howie Li
CEO of Shenzhen Falcon Network Technology Co., LtdHowie Li, CEO of Shenzhen Falcon Network Technology Co., Ltd, has been selected as one of “2021 Fortune 40 Chinese Business Elites under 40”. Before founding Beijing Qiguo Network Technology Co., Ltd, he had previously served in Cisco Systems (China) and IQIYI, and has gained seasoned experience in product, operation and technology related to the Internet industry. In 2018, He joined Falcon Technology as CEO, and successively proposed "Three Curves", "Scene Internet" and "from OTT ecology to Smart Screen ecology 1.0", which provided an important reference direction for the development of the industry. And he has led Falcon Technology to achieve a significant increase in the company's profitability and operational capabilities, based on three major methodologies of user insight, lean startup, and data-driven growth. In 2020, due to the fact that Falcon Technology’ s net profit reaching to HK$210 million and the revenue growth rate was more than three times over the overall industry growth rate, Falcon Technology has becoming a fast-growing quasi-unicorn company, and was listed in "2020 China's Top 100 Startups Most Watched by Investors" and “2020 China Gazelles 100".
Siping Li
前海母基金主管合伙人、投委会秘书长李思平，经济学硕士，2009年负责筹建深圳市创业投资引导基金并担任主要负责人，2016年加入前海母基金管理团队，担任主管合伙人、投委会秘书长，负责前海母基金的投资业务组织与综合运营管理工作，积累了丰富的政府引导基金和市场化母基金投资管理经验，对母基金的投资逻辑、运营机制、风险控制、投后管理有着深刻的理解和判断。前海方舟资产管理有限公司旗下包括前海母基金、中原前海基金、齐鲁前海基金、智慧互联产业基金、淮泽天使基金等六大基金投资平台，管理规模约600亿元。前海方舟聚焦科技产业，重点布局信息技术、生命科学、先进制造等领域，旗下基金直接/间接投资项目超过1600家，培育上市企业65家。
Yajun Li
临芯投资董事长在创立临芯投资之前，李亚军先生曾担任上海浦东科投管理合伙人、副总裁，联芯科技CFO，拥有近30年半导体行业投资及高级管理经验，长期在央企担任高级管理职务，兼具财务和产业背景，在通信和半导体领域有着深厚资源和人脉积累。
李亚军先生曾带领团队先后发起并主导了澜起科技、豪威科技等国内知名并购项目，已投企业澜起科技、中微公司成为科创板首批上市企业。2020年，他成功主导了中欣晶圆的混改及战略融资，再次树立了业界丰碑。
在2021年评选的“投中2020年投资人榜单”上，李亚军先生再度荣获“中国最佳先进制造产业投资人TOP10”，“中国最佳私募股权投资人TOP50”两项殊荣。
Ruby Lu
Founder and Managing Partner of Atypical VenturesRuby Lu is founder and managing partner of Atypical Ventures, a venture fund investing in early-stage companies in China. Prior to founding Atypical, she co-founded eCarX which commands a valuation of approximately US$3 billion in the private market. In 2003 Ruby co-founded DCM China and co-led the practice for over thirteen years. She led an investment in Kuaishou which returned over 1000x from her initial investment and billions in profit in a single deal. As a venture capitalist, she has led early-stage investments that generated 14 unicorn companies, 8 IPOs and 4 M&As. Prior to becoming a venture capitalist, Ruby was a Vice President in Goldman Sachs’ technology investment banking group. She was ranked as a top global technology investor by Forbes’ Midas List. She received an M.A. from Johns Hopkins University School of Advanced International Studies (SAIS) and a B.A. with honors from the University of Maryland.
Wangze Ni
CEO of Shenzhen Capital Group Co., Ltd倪泽望先生，南京航空航天大学机械设计制造专业全日制博士、中山大学企业管理专业在职博士，高级工程师，2015年加入深圳市创新投资集团，任党委书记、董事长至今。兼任中国证券投资基金业协会创业投资基金专委会联席主席、中国保险资产管理业协会股权投资专业委员会副主任委员、深圳市金融发展决策咨询委员会委员等。曾获评清科集团“2020年中国创业投资家10强”、全球母基金协会“2020全球最具影响力FOF投资人TOP50”第十一名等。
Sharon Shen
Managing Director at TPG Capital AsiaSharon Shen serves as a Managing Director at TPG Capital Asia, based in Hong Kong. Prior to joining TPG in 2018, Sharon served as a Senior Director with Alvarez & Marsal (A&M). Sharon holds a BBA (Hons) from the Chinese University of Hong Kong, and is also a FRM and CFA charter holder. Sharon currently serves on the Board of several TPG portfolio companies, including Duxiaoman, APM Monaco and CD Finance.
Carl Wu
Founder and CEO of New FrontierCarl Wu is the Founder and CEO of New Frontier, a patient-centric healthcare company in China. Since its inception in 2016, Mr. Wu led New Frontier from a start-up to an industry-leading healthcare group covering acute hospitals, outpatient / ambulatory services, rehabilitation hospitals, home health, oncology, health insurance and health technology, servicing approximately 10 million patients annually.
Mr. Wu is currently the President and Chairman of the Executive Committee of New Frontier Health / United Family Healthcare (NYSE: NFH). He is also the Executive Chairman and Co-founder of YD Care (home healthcare service provider), Heal Oncology (oncology group in the Greater Bay area), Boxful Technology (the leading on-demand storage service provider in Asia), HelloToby Technology (the leading online service marketplace in Hong Kong), and Precision Medical. Carl is also the Chairman of Care Alliance (the leading post-acute healthcare operator in China), and the Chairman of NF Greater Bay Area Health Holding.)
Prior to founding New Frontier, Mr. Wu was one of the youngest Managing Directors at Blackstone and executed some of Blackstone's most important investments in China. He was a founding member of Blackstone Asia and was instrumental in establishing Blackstone's businesses across China. Prior to moving to Hong Kong, Mr. Wu was based in Blackstone's London office, and has worked in Blackstone’s London, Hong Kong, Shanghai, and Beijing offices. Before joining Blackstone, he worked in investment banking at UBS in London.
Mr. Wu holds a Bachelor of Science in Economics from the London School of Economics, where he graduated with First Class Honors.
Bing Yuan
COO of Hony Capital袁兵先生于2009年4月加入弘毅投资，目前为弘毅投资的首席运营官（COO）和管理委员会成员。袁兵先生现在负责弘毅投资的全部股权业务的管理，包括弘毅私募股权投资（Private Equity），弘毅金涌对冲基金，弘毅远方公募基金，以及弘毅创投基金。总基金管理规模超过100亿美元。袁兵先生的主要投资案例包括TMT行业的巨人网络，今日头条；医疗行业的柏盛吉威，先声药业，东软医疗，天境生物；金融行业的上海农商行，中粮资本等。
加入弘毅投资之前（2008年8月至2009年2月），袁兵先生担任摩根士丹利直接投资部董事总经理，驻于香港，负责摩根士丹利在中国的直接投资业务。此前（2004年4月至2008年8月），袁兵先生曾任摩根士丹利中国企业融资业务董事总經理, 负责中国公司在海外的上市，融资和收购兼并业务。在加入摩根士丹利之前（1998年8月至2004年2月），袁兵先生任瑞士信贷第一波士顿副总裁，先后于纽约和香港办公室工作，负责科技、媒体和电信行业的企业融资和并购。袁兵先生在其投资银行职业期间协助众多中国知名的国有和民营企业成功完成了在海外的上市，融资和收购兼并项目。
加入瑞士信贷前（1993年7月至1995年8月），袁兵先生曾在纽约的富通资本担任项目融资的金融分析员。袁兵先生于1990年毕业于南京大学，取得英美文学学士学位，并于1993年获耶鲁大学国际关系硕士学位，1998年获耶鲁大学法学博士学位。
Vanessa Xu
Founding Partner, Chief Investment OfficerMs. Xu is Founding Partner and Chief Investment Officer of VS Partners. She has near-two-decades of experience in Asia Pacific capital markets across asset classes in public equity, private equity, private credit, and structured products, and pioneered the first independent Outsourced Chief Investment Officer (OCIO) asset allocation model in China.
Prior to founding VS Partners, Ms. Xu co-founded FountainCap Research & Investment Co., Ltd (“FountainCap”) , a well-known Greater China long-only equity manager with approximately $1.5bn asset under management from prominent sovereign-wealth fund, pension allocators, university endowments, long-term OCIO and family offices, and banking institutions. In her role as founding CEO between 07/2014 to 08/2019, FountainCap was awarded in two consecutive years (2018, 2019), the "Asset Management Company of the Year – China Equity Category" by The Asset, and in three consecutive years (2017, 2018, 2019) the Golden Bull China Overseas Long-Only Management Company of the Year.
Prior to founding FountainCap, Ms. Xu was an Investment Officer at Capital International Private Equity Funds (“CIPEF”), a subsidiary of the Capital Group. Prior to Capital Group, Ms. Xu was an investment banker at J.P. Morgan Securities (Far East) Ltd., Credit Suisse (Hong Kong) Co., Ltd and Citigroup Global Markets Asia Ltd. Prior to that, Ms. Xu was a management consultant at Monitor Group in Beijing in the early 2000s.
Ms. Xu received a B.A. of International Economics from Peking University, China, a M.A. of Economics from the Ohio State University, the U.S., and EMBA degree from China Europe International Business School. Ms. Xu is a Fellow of the Aspen China Fellowship Program and a member of the Aspen Global Leadership Network.
Shirley Yeung
Founder and Managing Partner of Dragonrise CapitalMs. Yeung is the founder and Managing Partner of Dragonrise Capital based in Shanghai, China. Born in China, and educated in both China and USA, she is one of the earliest venture capitalists investing in mainland China. In past 20 years she has been instrumental in investments in and financing of a number of high profile and successful Chinese internet startups which are now multi-billion dollar public companies, impacting the daily lives of almost all Chinese citizens today. These include the Series A round investment in Tencent Technologies (HKSE:700), the largest internet media/gaming company in China with about USD500 billion in market cap investments, which also owns the Wechat platform with 800 million users worldwide as the largest Chinese social media platform in the world; also investments in Sohu.com and Sina.com, and Focus Media Holdings (the largest Chinese outdoor media company) and GCL-Poly Energy (the leading poly-silicon and wafer suppliers in the world). She remains an active VC investor in China managing new funds investing in startups in Artificial Intelligence related technologies and applications area.
Prior to her return to mainland China, Shirley was Director of Venture Investments at PCCW in Hong Kong from 2000 to 2003. Before that she worked for JP Morgan as a Vice President in Equity Capital Markets Group in Hong Kong office from 1997 to 2000 and participated in the advisory and execution of the earliest and largest Chinese SOE privatization transactions including the overseas IPOs of China Telecom, China Mobile and Unicom etc. Prior to relocating back to Asia, Shirley managed a pension fund portfolio of $3.5 billion in non-U.S. equity investments for NYNEX Asset Management Company in New York City, now part of Verizon Investment Management Corp, one of the largest Private Pension Fund Managers in USA.
As part of her contributions to the Chinese venture capital and investment industry, Shirley served a two-year term in Beijing between 2014-2015 as Executive Chairwoman of the Investment and Financing Committee, under the MOFCOM sponsored China Council for International Investment Promotion, responsible for promoting cross-border venture capital and private equity investments between China and overseas markets. Shirley received an MBA in Finance from Yale University School of Management in 1993, and is currently a Member of Yale SOM Global Advisory Board. She is married with two children who both graduated from Yale recently.
Wei Zhou
Founding Partner of CCVWei is the founding partner of China Creation Ventures (CCV). He is a resourceful venture capitalist, a successful serial entrepreneur in technology, and a pioneer of Chinese digital payment industry. Before becoming an investor, Wei has accumulated more than 10 years of experience in technology innovation and business management. In 1993, Wei joined Fujian Start Group as a founding member and became the youngest executive officer. He oversaw the group’s corporate strategy and M&A and took the company to IPO on Shanghai Stock Exchange in 1996. He then served as the CEO and the Board President of Shanghai Hanbo Technologies. Under Wei’s management, Hanbo enjoyed years of rapid growth and was acquired at high valuation.
In 2007, Wei joined KPCB as a founding member and Managing Partner of the China office. During the 10 years at KPCB, Wei led the TMT investments in Greater China. Within the 29 TMT companies Wei invested in, 11 have become unicorns, 1 has achieved over 500x return, and 4 have achieved over 100x return.
In 2017, Wei founded CCV with the original TMT investment team at KPCB China. CCV sticks to “selective investments strategy” and focuses on early and growth stage investments Enterprise Solutions, Digital Healthcare, Advanced Technologies, and New Generation in China. CCV currently manages over 500 million in USD and 2.5 billion in RMB. Since its establishment, CCV has already delivered 2 IPOs and 4 unicorns (within which 2 are valued at over 10 billion USD). By far, under the “selective investments strategy”, Wei has successfully invested in at least 1 unicorn every year on average during his 14 years of investment career.
The star companies that Wei backed at early stages include:
E-commerce: JD (NASDAQ: JD), WeCook.
Social Network and Contents: Ximalaya, TanTan (Acquired by MoMo
NASDAQ: MOMO), MetaApp, Asia Innovations Group, Joyrun, Colorful Pines.
Fintech: CreditEase (NYSE: YRD), Rong360 (NYSE: JT), JD Technologies,
IceKredit, Transsnet Finance.
Artificial Intelligence: Perfect Corp., Cowa Robot, Quicktron, Hitbot, Singsound.
Digital Healthcare: Shukun Technology, Arrail Dental, Yunhu Technology, Naxions, Rivamed, Jarvis.
Enterprise Solutions: VenusTech (SZSE: 002439), Wanka Online (HKSE: 1762), Mininglamp Technology, Eccang, Ele007.
With his successful investment track record, Wei has been given numerous awards such as Forbes China’s Top 30 Venture Capitalists for four consecutive years, Fortune Top 30 Most Influential Investors of 2020, 36Kr Top 35 Investors Most Welcomed by Entrepreneurs, and Best Investor of the Year awarded by Zero2IPO and China Venture respectively.
Wei holds an MBA degree from the Wharton Business School and a bachelor’s degree in Engineering from the University of Electronic Science and Technology of China. He serves as the treasurer of China Venture Capital and Private Equity Association (“CVCA”), and long-term entrepreneurship mentor at Wharton Business School, Tsinghua PBC School of Finance, and Zero2IPO Sandhill College.
Edward Zhou
Founding Managing Partner, Hanne CapitalPrior to founding Hanne Capital in early 2017, Mr. Zhou was IC member and partner in charge of healthcare investments at New Horizon Capital for 9 years. Under his leadership the team has made investments across all segments of healthcare industry including a number of landmark deals.
His representative portfolios include Zylox Ton-Bridge Medical(HK:02190), HiFiBio, Biotheus, Shulan Healthcare, United Imaging, Microport Endovascular (SH: 688016), SinoMed (SH: 688108), ZaiLab(NASAQ: ZLAB), Scion Medtech (NYSE: VAR), Hile Bio-tech (SH: 603718)，HEC Changjiang Pharma (HK:1558)，OrbiePharm and Allgens(SH: 688613).
Mr. Zhou was a founding partner of Qiming Ventures before joining New Horizon in 2008. Early in his investment career Mr. Zhou was a strategic investment director at Cisco Systems where he was responsible for strategic investments, M&A as well as strategic partnership in Asia Pacific region. Mr. Zhou has over 18 years of investment experience with the last 12 years focusing on healthcare industry.
Mr. Zhou holds an MBA degree from Kellogg School of Management, Northwestern University as well as bachelor and master degrees both from Shanghai Jiao Tong University.
About Hanne Capital
Founded in 2017, Hanne Capital is a healthcare specialty private equity investment fund focusing on growth opportunities in Greater China. The founding partners are all veterans with years of senior leadership experience at industry leading private equity fund or world-renowned multinationals in pharma, medtech & biotech industries. Each founding partner has achieved industry milestones in their previous career. Hanne team consists of seasoned professionals with sharp business acumen and rich experience of investments and believes strongly in high standards of ethics and professionalism.
Historically the founding partners have deployed over US$330 million into a number of companies and played pivotal roles in the growth of these investees. Many of our portfolios have successfully listed on renowned stock exchanges in mainland China, US, Hong Kong and Taiwan with a collective market capitalization over US$10 billion.
We look for companies with great growth potential in pharma & biotech, medtech and healthcare services sectors and choose to work with management teams with integrity and solid execution capabilities. We will work closely with our portfolios as an extended team to create value by leveraging our broad network of connections and deep domain expertise in growth strategy, business developments, cross-border IP transactions and operation improvements.